Alice Y. Chang, M.D.

The purpose of this study is to determine if cardiometabolic risk correlates with the estradiol (E) to testosterone (T) ratio or circulating concentrations, cross sex hormone duration or route, and to determine if changes in the E/T ratio are associated with changes in insulin sensitivity, body composition and adipose tissue fatty acid metabolism in transgender women.

The purpose of this study is to evaluate the effectiveness and safety of  ATR-101 for the treatment of adults who have internally caused Cushings syndrome.

This is a Phase 2 multicenter, single-blind, multiple dose study to evaluate the safety and efficacy of orally administered ATR-101 in subjects with classic congenital adrenal hyperplasia (CAH). Treatment duration will range from a minimum of approximately 2 months to 6 months per subject. A subject may receive a minimum of one dose level or up to a maximum of 5 dose levels, in sequentially increasing dose strengths. Each dose level will last 28 days.

The purpose of this study is to evaluate the blood chemistry, genetics, and eye exams in women with polycystic ovary syndrome and/or intracranial hypertension. Similar studies are being completed with astronauts. The results may help us better understand the nature, and ultimately the treatment of polycystic ovary syndrome, intracranial hypertension, and astronaut eye and vision issues.

The investigator's global hypothesis is that women with Polycystic Ovary Syndrome (PCOS) can be separated into subtypes based on their response to metformin. The investigators propose here to use both targeted and non-targeted metabolomic approach to identify pathways associated with metformin's effect on insulin sensitivity and endothelial function. This pilot project will be the foundation for developing tailored therapeutic approaches to Polycystic Ovary Syndrome and identifying novel drug targets.